tildrakizumab (Ilumya)
Jump to navigation
Jump to search
Indications
- chronic plaque psoriasis*
* 80% with 75% clearance after etanercept failure[1]
Dosage
- 100-200 mg every 4 weeks?
Mechanism of action
- monoclonal antibody against IL-23 p19
More general terms
References
- ↑ 1.0 1.1 Bankhead C American Academy of Dermatology Meeting Coverage 2017 Psoriasis Responds After Biologic Failure
PASI-75 rate exceeds 80% with tildrakizumab. http://www.medpagetoday.com/MeetingCoverage/AAD/63635 - ↑ American Academy of Dermatology Reich K, et al Tildrakizumab, ak selective anti-IL-23 monoclonal antibody, is effective in subjects with chronic plaque psoriasis who do not adequately respond to etanercept American Academy of Dermatology (AAD) 2017; Abstract 5252.
- ↑ Papp K, et al Maintenace of treatment response in chronic plaque psoriasis patients continuing treatment or discontinuing treatment with tildrakizumab in a 64-week, randomized controlled phase III trial. American Academy of Dermatology (AAD) 2017; Abstract 4885.
- ↑ 4.0 4.1 Brooks M FDA Clears Tildrakizumab (Ilumya ) for Plaque Psoriasis. Medscape - Mar 21, 2018. https://www.medscape.com/viewarticle/894314
- ↑ Thaci D, Piaserico S, Warren RB et al Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol. 2021 Aug;185(2):323-334 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33544883 Clinical Trial.
Lebwohl MG, Leonardi CL, Mehta NN et al Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). J Am Acad Dermatol. 2021 Feb;84(2):398-407. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32961255 Free article